I agree it looks cheap assuming they can maintain similar cashflows for the rest of the financial year.
UWL you have to look forward and they are forecasting EBITDA in excess of $17m, with a management team with huge runs on the board.
ST1 looks to be at turning point with the appointment of Sol as the new MD and over $8m available for acquisitions. Sol has already been instrumental in improving sales performance since he started a year ago.
All have a lot of upside in my opinion. I agree 5GN looks the most undervalued and it will re-rate if they continue to show consistent earnings growth.
Ann: Appendix 4C - quarterly, page-14
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 5GN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $44.26M | |||
| Open | High | Low | Value | Volume |
| 14.5¢ | 14.8¢ | 14.5¢ | $14.50K | 99.82K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1828966 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 3419686 | 23 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| 5GN (ASX) Chart |